Nektar Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013 - 1994
Net Income	-276.06	-368.2	-523.84	-444.44	-440.67	681.31	-96.69	-153.52	-81.18	-53.92	Upgrade
Depreciation & Amortization	7.82	13.03	14.15	14.18	13.16	10.87	14.74	15.35	12.86	12.93	Upgrade
Share-Based Compensation	33.39	57.32	94.67	94.26	99.8	88.1	36.62	25.85	19.67	17.02	Upgrade
Other Operating Activities	42.25	-6.16	2.36	22.71	-0.97	-62.07	-35.08	-4.7	-24.43	-118.03	Upgrade
Operating Cash Flow	-192.61	-304.01	-412.66	-313.29	-328.68	718.21	-80.41	-117.02	-73.08	-142.01	Upgrade
Capital Expenditures	0.38	7.52	-14.99	-7.26	-26.29	-11.61	-9.68	-6.39	-11.2	-9.98	Upgrade
Change in Investments	139.18	358.32	217.77	503.47	233.17	-1,368.33	-19.13	-76.01	-28.14	-27.6	Upgrade
Other Investing Activities	-	-	-	-	-	-	-	-	25	-	Upgrade
Investing Cash Flow	139.56	365.84	202.78	496.21	206.89	-1,379.94	-28.81	-82.4	-14.34	-37.57	Upgrade
Share Issuance / Repurchase	0.03	0.76	33.24	23.4	23.36	851.97	59.52	209.56	32.21	163.52	Upgrade
Debt Issued / Paid	0	0	0	-250	0	0	-5.13	-5.95	111.08	-3.54	Upgrade
Other Financing Activities	-	0.75	3	146.25	-	-	-	-	-12.5	-7	Upgrade
Financing Cash Flow	0.03	1.51	36.24	-80.35	23.36	851.97	54.39	203.62	130.78	152.98	Upgrade
Exchange Rate Effect	0.06	-0.33	-0.09	0.02	-0.1	-0.1	-0.05	-0.12	-0.16	-0.11	Upgrade
Net Cash Flow	-52.95	63.01	-173.74	102.59	-98.54	190.14	-54.88	4.07	43.21	-26.7	Upgrade
Free Cash Flow	-192.23	-296.49	-427.65	-320.55	-354.97	706.61	-90.09	-123.42	-84.28	-151.98	Upgrade
Free Cash Flow Margin	-213.30%	-322.08%	-419.65%	-209.62%	-309.70%	59.21%	-29.28%	-74.60%	-36.52%	-75.72%	Upgrade
Free Cash Flow Per Share	-1.01	-1.58	-2.33	-1.79	-2.03	4.17	-0.58	-0.88	-0.64	-1.20	Upgrade

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).